A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, ...

Michael Aycock says he couldn't believe the price of his most recent prescription, but he's hoping to overcome his illness without breaking the bank. Aycock was diagnosed with covid and got a ...

At Shionogi, a Japanese pharmaceutical company, executives pointed out that COVID is still flaring in Japan. In Japan, ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | ...

MEDICAL CARE CAN BE EXPENSIVE, AS WE ALL KNOW, BUT THAT’S WHERE HEALTH INSURANCE IS SUPPOSED TO COME IN TO ALLEVIATE THE COST ...

COVID-19 clinical rebound following treatment with nirmatrelvir-ritonavir (Paxlovid) was generally mild and associated with favorable outcomes.

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ...

NEW YORK — A boost from Covid-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher ...

Pfizer's third-quarter performance exceeded expectations, driven by a surge in demand for its COVID-19 treatment Paxlovid, ...

Pfizer reported higher-than-expected profits driven by strong Paxlovid sales, offsetting a decline in COVID vaccine sales.

Pfizer reported higher-than-expected profit due to strong sales of COVID-19 treatment Paxlovid. Despite this success, the ...